Anovo Blog

Eton Pharmaceuticals  & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency

January 23, 2025

Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their commitment to addressing underserved conditions has led to the acquisition of INCRELEX®, the only FDA-approved therapy for children and adolescents aged 2 to 18 with severe primary insulin-like growth factor 1 deficiency (SPIGFD). 

What is Severe Primary Insulin-Like Growth Factor 1 Deficiency?

SPIGFD is a rare and serious condition that impacts growth and development. Children with this condition don’t produce enough insulin-like growth factor 1 (IGF-1), a hormone essential for normal growth. This leads to severe growth failure, often with symptoms like short stature and developmental delays. While SPIGFD affects only about 200 children in the U.S., its impact on their lives is profound, making timely and effective treatment crucial.

Eton Pharmaceuticals Partners with Anovo

Anovo is proud to partner with Eton Pharmaceuticals as the exclusive distributor and specialty pharmacy for INCRELEX®. Through the Eton Cares program, we’re ensuring patients and families receive the specialized support they need—through prescription fulfillment, education, insurance assistance, and financial support for qualifying families. Together, we are empowering patients and caregivers with the resources and care they need to manage this rare disease.

---

Related Posts